Steffen Björn, Müller-Tidow Carsten, Schwäble Joachim, Berdel Wolfgang E, Serve Hubert
Department of Medicine, Hematology/Oncology, University of Münster, Albert-Schweitzer-Strasse 33, 48129 Münster, Germany.
Crit Rev Oncol Hematol. 2005 Nov;56(2):195-221. doi: 10.1016/j.critrevonc.2004.10.012. Epub 2005 Oct 19.
The description of the molecular pathogenesis of acute myeloid leukemias (AML) has seen dramatic progress over the last years. Two major types of genetic events have been described that are crucial for leukemic transformation: alterations in myeloid transcription factors governing hematopoietic differentiation and activating mutations of signal transduction intermediates. These processes are highly interdependent, since the molecular events changing the transcriptional control in hematopoietic progenitor cells modify the composition of signal transduction molecules available for growth factor receptors, while the activating mutations in signal transduction molecules induce alterations in the activity and expression of several transcription factors that are crucial for normal myeloid differentiation. The purpose of this article is to review the current literature describing these genetic events, their biological consequences and their clinical implications. As the article will show, the recent description of several critical transforming mutations in AML may soon give rise to more efficient and less toxic molecularly targeted therapies of this deadly disease.
在过去几年中,急性髓系白血病(AML)分子发病机制的描述取得了显著进展。已描述了两种对白血病转化至关重要的主要基因事件类型:调控造血分化的髓系转录因子的改变以及信号转导中间体的激活突变。这些过程高度相互依赖,因为改变造血祖细胞转录控制的分子事件会改变可用于生长因子受体的信号转导分子的组成,而信号转导分子中的激活突变会诱导几种对正常髓系分化至关重要的转录因子的活性和表达发生改变。本文的目的是综述描述这些基因事件、其生物学后果及其临床意义的当前文献。正如本文将展示的,AML中几种关键转化突变的最新描述可能很快会带来针对这种致命疾病的更有效且毒性更小的分子靶向疗法。